|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Genetic alterations in pancreatic cancer显示文摘The diagnosis of pancreatic cancer is devastating for patients and their relatives as the incidence rate is approximately the same as mortality rate. Only a small percentage, which ranges from 0.4% to 4% of patients who have been given this diagnosis, will be alive at five years. At the time of diagnosis, 80% of pancreatic cancer patients have unresectable or metastatic disease. Moreover, the therapeutic alternatives offered by chemotherapy or radiotherapy are few, if not zero. For all these reasons, there is an imperative need of analyzing and understanding the primitive lesions that lead to invasive pancreatic adenocarcinoma. Molecular pathology of these lesions is the key of our understanding of the mechanisms underlying the development of this cancer and will probably help us in earlier diagnosis and better therapeutic results. This review focuses on medical research on pancreatic cancer models and the underlying genetic alterations. | Muhammad Wasif Saif Lena Karapanagiotou Kostas Syrigos | 2007 | World Journal of Gastroenterology2007，13，33： | 10 |
| 2 | Incidence and management of ZIv-aflibercept related toxicities in colorectal cancer显示文摘Ziv-afilbercept(Zaltrap, Ziv) is a humanized fusion protein constructed by joining the vascular endothelial growth factor(VEGF) binding portions of human VEGF receptors 1 and 2 to the Fc portion of human immunoglobulin IgG 1. Recently, a randomized, open-label, phase Ⅲ study compared 5-fluorouracil, leucovorin, irinotecan(FOLFIRI)/Ziv with FOLFIRI/placebo in patients who had been previously treated with oxaliplatin based chemotherapy for metastatic colon cancer(mC RC). Patients who had received prior bevacizumab therapy were also eligible. This study showed that the addition of Ziv improved overall survival with median survival time of 13.5 mo vs 12.06 mo in ziv vs placebo arm. Ziv also improved progression free survival from 4.67 mo to 6.9 mo with a response rate of 19.8% in the Ziv/FOLFIRI group vs 11.1% in FOLFIRI alone group. This led to the approval of Ziv in combination with FOLFIRI in metastatic colon cancer patients treated with prior oxaliplatin regimens. The mostcommon side effects were diarrhea, stomatitis, fatigue, hypertension, weight loss, loss of appetite, abdominal pain, and headache. As the use of Ziv has become more widespread in oncology practices, familiarity with the toxicity profile of the drug and the use of practice guidelines for their treatment has become increasing important. This review will address the toxicities noted in trials using Ziv for the treatment of mC RC, and will provide recommendations for toxicity management. | Muhammad Wasif Saif Valerie Relias Kostas Syrigos Krishna S Gunturu | 2014 | World Journal of Clinical Oncology2014，5，5： | 5 |
| 3 | Fever as the only manifestation of hypersensitivity reactions associated with oxaliplatin in a patient with colorectal cancer Oxaliplatin-induced hypersensitivity reaction显示文摘Hypersensitivity reactions (HSR) to oxaliplatin in patients with colorectal cancer include facial ushing, erythema, pruritis, fever, tachycardia, dyspnea, tongue swelling, rash/hives, headache, chills, weakness, vomiting, burning sensations, dizziness, and edema. We report a patient with fever as the sole manifestation of initial HSR, review the literature and discuss the management of HSR. A 57-year-old female with T3N2M0 rectal adenocarcinoma received modified FOLFOX-6. She tolerated the first 8 cycles without any toxicities except grade 1 peripheral neuropathy and nausea. During 9th and 10th infusions, she developed fever to a maximum of 38.3℃ with stable hemodynamic status despite medications. During 11th infusion, she developed grade 3 HSR consisting of symptomatic bronchospasm, hypotension, nausea, vomiting, cough, and fever. On examination, she was pale, cyanotic, with a temperature of 38.8℃, BP dropped to 95/43 mm Hg, pulse of 116/min and O2 saturation of 88%-91%. She was hospitalized for management and recovered in 24 h. Fever alone is not a usual symptom of oxaliplatin HSR. It may be indicative that the patient may develop serious reactions subsequently, as did our patient who developed hypotension with the third challenge. Treatment and prevention consists of slowing the infusion rate, use of steroids and antagonists of Type 1 and 2 histamine receptor antagonists, whereas desensitization could help to provide the small number of patients who experience severe HSR with the ability to further receive an effective therapy for their colorectal cancer. | M Wasif Saif Shailja Roy Leslie Ledbetter Jennifer Madison Kostas Syrigos | 2007 | World Journal of Gastroenterology2007，13，39： | 4 |
| 4 | Disparities in colorectal cancer in African-Americans vs Whites: Before and after diagnosis显示文摘There are differences between African-American and white patients with colorectal cancer, concerning their characteristics before and after diagnosis. Whites are more likely to adhere to screening guidelines. This is also the case among people with positive family history. Colorectal cancer is more frequent in Blacks. Studies have shown that that since 1985, colon cancer rates have dipped 20% to 25% for Whites, while rates have gone up for African-American men and stayed the same for African-American women. Overall, African-Americans are 38% to 43% more likely to die from colon cancer than are Whites. Furthermore, it seems that there is an African-American predominance in right-sited tumors. African Americans tend to be diagnosed at a later stage, to suffer from better differentiated tumors, and to have worse prognosis when compared with Whites. Moreover, less black patients receive adjuvant chemotherapy for resectable colorectal cancer or radiation therapy for rectal cancer. Caucasians seem to respond better to standard chemotherapy regimens than AfricanAmericans. Concerning toxicity, it appears that patients of African-American descent are more likely to develop 5-FU toxicity than Whites, possibly because of their different dihydropyridine dehydrogenase status. Last but not least, screening surveillance seems to be higher among white than among black long-term colorectal cancer survivors. Socioeconomic and educational status account for most of these differences whereas little evidence exists for a genetic contribution in racial disparity. Understanding the nature of racial differences in colorectal cancer allows tailoring of screening and treatment interventions. | Anastasios Dimou Kostas N Syrigos Muhammad Wasif Saif | 2009 | World Journal of Gastroenterology2009，15，30： | 2 |
| 5 | 在周期性的 glucagonoma 的骨头损害: 一份案例报告和文学的评论显示文摘 Glucagonomas are rare neuroendocrine tumors that arise from cells of the pancreatic islets. Most of them are malignant and usually present as metastatic disease. Sites most commonly involved in metastases are the liver and regional lymph nodes. Bone metastases are rare events and only a few cases have been reported in the literature. We present the case of a 53-year-old male with a medical history of recurrent non-functioning glucagonoma. He presented 17 years after the initial diagnosis with new blastic bone lesions involving the T1 vertebra and the sacrum. Diagnostic steps and medical management in metastatic glucagonoma are also reviewed. | Cristian Ghetie Daniel Cornfeld Vassilios S Ramfidis Kostas N Syrigos Muhammad W Saif | 2012 | World Journal of Gastrointestinal Oncology2012，4，6： | 2 |
| 6 | Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial显示文摘 | Edward B Garon Tudor-Eliade Ciuleanu Oscar Arrieta Kumar Prabhash Konstantinos N Syrigos Tuncay Goksel Keunchil Park Vera Gorbunova Ruben Dario Kowalyszyn Joanna Pikiel Grzegorz Czyzewicz Sergey V Orlov Conrad R Lewanski Michael Thomas Paolo Bidoli Shaker | 2014 | The Lancet2014，，： | 2 |
| 7 | Gastric cancer in the elderly: An overview显示文摘 | M.W. Saif N. Makrilia A. Zalonis M. Merikas K. Syrigos | 2010 | European Journal of Surgical Oncology2010，，8： | 2 |
| 8 | The VEGF pathway in lung cancer显示文摘 | Michalis Alevizakos Serafim Kaltsas Konstantinos N. Syrigos | 2013 | Cancer Chemotherapy and Pharmacology2013，，6： | 2 |
| 9 | Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go?显示文摘Pancreatic adenocarcinoma(usually referred to aspancreatic cancer) is a highly lethal and aggressive malignancy with a disease-related mortality almost equaling its incidence, and one of the most challenging cancers to treat. The notorious resistance of pancreatic cancer not only to conventional cytotoxic therapies but also to almost all targeted agents developed to date, continues to puzzle the oncological community and represents one of the biggest hurdles to reducing the death toll from this ominous disease. This editorial highlights the most important recent advances in preclinical and clinical research, with regards to targeted therapeutics for pancreatic cancer, outlines current challenges and provides an overview of potential future perspectives in this rapidly evolving field. | Dimitra Grapsa Muhammad Wasif Saif Konstantinos Syrigos | 2015 | World Journal of Gastrointestinal Oncology2015，7，10： | 2 |
| 10 | Circulating vegf levels in the serum of gastric cancer patients:Correlation with pathological variables,patient survival,and tumor surgery显示文摘 | Karayiannakis AJ Syrigos KN Polychronidis A | 2002 | Ann Surg2002，236，： | 1 |
| 11 | Expression patterns of the novel catenin p120cas in gastrointestinal cancers显示文摘 | Karayiannakis AJ Syrigos KN Alexiou D | 1999 | Anticancer Res1999，19，5： | 1 |
| 12 | Expression patterns of alpha-,beta-and gamma-catenin in pancreatic cancer:correlation with E-cadherin expression,pathological features and prognosis显示文摘 | Karayiannakis AJ Syrigos KN Polyehronidis A | 2001 | Anticancer Res2001，21，6： | 1 |
| 13 | Circulating VEGF levels in the serum of gastric cancer patients:correlation with pathological variables, patient survival,and tumor surgery 显示文摘 | KARAYIANNAKIS AJ SYRIGOS KN POLYCHRONIDIS A | 2002 | Ann Surg2002，236，1： | 1 |
| 14 | Targeted therapy for oesophageal cancer:an overview显示文摘 | Syrigos KN Zalonis A Kotteas E | | 0，，02： | 1 |
| 15 | Novel agents and future pros- pects in the treatment of pancreatic adenarcinoma 显示文摘 | Sarris EG Syrigos KN Saif MW | 2013 | JOP2013，14，4： | 1 |
| 16 | Circu- lating VEGF levels in the serum of gastric cancer patients 显示文摘 | Karayiannakis A Syrigos KN Polychronidis A | 2002 | Ann Surg2002，236，： | 1 |
| 17 | Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery显示文摘 | Karayiannakis A J Syrigos KN Polychronidis A | 2002 | Ann Surg2002，236，1： | 1 |
| 18 | Novel agents and new combination treatments on phase Ⅰ studies on solid tumors and pancreatic cancer显示文摘 | Strimpakos AS Syrigos KN Saif MW | 2012 | JOP2012，13，4： | 1 |
| 19 | Capecitabine: an overview of the side effects and their management显示文摘 | Muhammad Wasif Saif Nikos A. Katirtzoglou Kostas N. Syrigos | 2008 | Anti-Cancer Drugs2008，，5： | 1 |
| 20 | S-1:a promising new oral fluoropyrimidine derivative显示文摘 | Saif MW Syrigos KN Katirtzoglou NA | 2009 | Expert Opin Investig Drugs2009，18，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员